148 related articles for article (PubMed ID: 38258995)
1. FDA grants approval to the RSV vaccine (nirsevimab-alip) for all infants: a leap forward for shielding the smallest.
Nazir A; Fatima R; Nazir A
Int J Surg; 2023 Dec; 109(12):3745-3746. PubMed ID: 38258995
[No Abstract] [Full Text] [Related]
2. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Cieslak CM
Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
[TBL] [Abstract][Full Text] [Related]
3. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
[TBL] [Abstract][Full Text] [Related]
4. Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
Gomez GB; Nelson CB; Rizzo C; Shepard DS; Chaves SS
J Infect Dis; 2022 Aug; 226(Suppl 2):S293-S299. PubMed ID: 35968865
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
6. Nirsevimab: First Approval.
Keam SJ
Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
[TBL] [Abstract][Full Text] [Related]
7. FDA Approves Maternal RSV Vaccine.
Harris E
JAMA; 2023 Sep; 330(11):1029. PubMed ID: 37647088
[No Abstract] [Full Text] [Related]
8. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
9. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
[TBL] [Abstract][Full Text] [Related]
11. Development of mRNA vaccines against respiratory syncytial virus (RSV).
Qiu X; Xu S; Lu Y; Luo Z; Yan Y; Wang C; Ji J
Cytokine Growth Factor Rev; 2022 Dec; 68():37-53. PubMed ID: 36280532
[TBL] [Abstract][Full Text] [Related]
12. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
Jorgensen SCJ
J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
[TBL] [Abstract][Full Text] [Related]
13. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
[TBL] [Abstract][Full Text] [Related]
14. Latest FDA-approved drug nirsevimab-alip (Beyfortus): A gamechanger for treatment of respiratory syncytial virus.
Talha M; Ali MH
J Med Virol; 2023 Oct; 95(10):e29169. PubMed ID: 37815045
[No Abstract] [Full Text] [Related]
15. RSV vaccines score landmark FDA approvals.
Kingwell K
Nat Rev Drug Discov; 2023 Jul; 22(7):523-525. PubMed ID: 37258651
[No Abstract] [Full Text] [Related]
16. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
18. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
Browne SK; Beeler JA; Roberts JN
Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
[TBL] [Abstract][Full Text] [Related]
19. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
